We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Judge

Daniel P Judge MD

Professor of Medicine/Cardiology, Section of Advanced HF & Transplant Cardiology, Director, Cardiovascular Genetics, Fellowship Director, Cardiology, Medical University of South Carolina (MUSC), Charleston, SC
As a cardiologist and translational scientist, Dr. Judge's research is focused on monogenic forms of cardiovascular disease, with particular emphasis on heart failure. He is the Director of the MUSC Cardiovascular Genetics program and the fellowship director for Cardiovascular Disease at MUSC. His post-doctoral research at Johns Hopkins University was focused on the molecular pathogenesis and translational treatments for Marfan syndrome and other inherited aortic diseases. For the past fifteen years, his research program has focused on the genetic basis and pathogenesis of inherited heart disease, with translational research trials investigating novel therapies targeting key factors involved with disease pathogenesis. 

Disclosures

Dr. Judge reports the following disclosures: payment as a scientific advisor from ADRx, 4D Molecular Therapeutics, Pfizer, and Blade Therapeutics. He is co-patent-holder for “TGFbeta Antagonists, Including AT1 Receptor Blockers, Rescue the Multi system Pathogenesis of Marfan Syndrome.” US Patent # 8,597,646.